Salta al contenuto principale
Passa alla visualizzazione normale.

VALERIO MARIA BARTOLO BRUCATO

Engineering approaches in siRNA delivery

  • Autori: Barba, A.; Cascone, S.; Caccavo, D.; Lamberti, G.; Chiarappa, G.; Abrami, M.; Grassi, G.; Grassi, M.; Tomaiuolo, G.; Guido, S.; Brucato, V.; Carfì Pavia, F.; Ghersi, G.; La Carrubba, V.; Abbiati, R.; Manca, D.
  • Anno di pubblicazione: 2017
  • Tipologia: Articolo in rivista (Articolo in rivista)
  • Parole Chiave: Delivery vectors; in vitro models; Mathematical modeling; Physical modeling; siRNAs; 3003
  • OA Link: http://hdl.handle.net/10447/241989

Abstract

siRNAs are very potent drug molecules, able to silence genes involved in pathologies development. siRNAs have virtually an unlimited therapeutic potential, particularly for the treatment of inflammatory diseases. However, their use in clinical practice is limited because of their unfavorable properties to interact and not to degrade in physiological environments. In particular they are large macromolecules, negatively charged, which undergo rapid degradation by plasmatic enzymes, are subject to fast renal clearance/hepatic sequestration, and can hardly cross cellular membranes. These aspects seriously impair siRNAs as therapeutics. As in all the other fields of science, siRNAs management can be advantaged by physical-mathematical descriptions (modeling) in order to clarify the involved phenomena from the preparative step of dosage systems to the description of drug-body interactions, which allows improving the design of delivery systems/processes/therapies. This review analyzes a few mathematical modeling approaches currently adopted to describe the siRNAs delivery, the main procedures in siRNAs vectors’ production processes and siRNAs vectors’ release from hydrogels, and the modeling of pharmacokinetics of siRNAs vectors. Furthermore, the use of physical models to study the siRNAs vectors’ fate in blood stream and in the tissues is presented. The general view depicts a framework maybe not yet usable in therapeutics, but with promising possibilities for forthcoming applications.